Protagonist Therapeutics, Inc. PTGX

PTGX Company Overview

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the discovery and development of peptide-based therapeutics for hematologic and immunologic diseases. The company operates within the biotechnology and specialty pharmaceutical industries, using a proprietary peptide technology platform to develop orally delivered and injectable peptide medicines designed to target clinically validated biological pathways. Its primary value drivers are its late-stage and clinical-stage therapeutic candidates, strategic licensing agreements, and collaboration revenue from larger pharmaceutical partners.

The company’s most prominent programs include rusfertide, an investigational hepcidin mimetic being developed for polycythemia vera and other blood disorders, and the oral IL-23 receptor antagonist program partnered with Johnson & Johnson through Janssen Biotech, Inc. Protagonist was founded in 2006 and evolved from a peptide discovery platform company into a clinical-stage biotechnology developer with multiple partnered and wholly owned assets. Its strategic positioning is supported by specialized expertise in constrained peptide engineering, a focused therapeutic portfolio, and collaborations with established global pharmaceutical companies.